About the project
AccessAfrica is a funded EDCTP2 project. The Project is coordinated by Dr. Rosemarie de la Cruz Bernabe from the Centre of Medical Ethics of the University of Oslo and Implemented by six institutions in Ethiopia and Uganda.
Objectives
The objectives of AccessAfrica are to:
- understand the status quo of post-trial access (PTA) in high-priority clinical trials within the region;
- provide practical guidance on how PTA can be enforced within the region; and
- develop and facilitate a PTA training workshop for national ethics committees, drug regulatory agencies, and Institutional Review Boards to enforce the oversight of this ethical imperative.
Background
With an increased number of clinical trials in Low- and Middle- Income Countries (LMICs) in the last 10 years and the fact that most of the trials are funded, sponsored, and influenced by private and public entities from high-income countries, there is a risk of exploiting research participants from LMICs. The research participants from LMICs countries risk delayed or no access to developed products and generated knowledge obtained from clinical trials. Access Africa aims to contribute to the capacity of national ethics committees and the relevant drug regulatory agencies in sub-Saharan Africa, in particular Ethiopia and Uganda, to integrate Post-Trial Access (PTA) oversight in their functions.
Financing
This Project is part of EDCTP2 program supported by the European Union.
Cooperation
The project is coordinated by the University of Oslo in Norway and implemented by Jimma University, St. Paul's Hospital Millennium Medical College, Armauer Hansen Research Institute, and Ministry of Science and Higher Education in Ethiopia and Uganda National Health Research Organisation and Uganda National Council for Science and Technology in Uganda.
Project start and finish
The Project started on December 1, 2020 and will last for 40 months.
This project is part of the EDCTP2 programme supported by the European Union